Core Viewpoint - Alto Neuroscience's Phase 2b study of ALTO-100 for major depressive disorder did not meet its primary endpoint, leading to a significant drop in share price [2]. Investigation Details - On October 22, 2024, Alto Neuroscience announced that the Phase 2b study did not achieve its primary endpoint as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) compared to placebo [2]. - Following this announcement, shares of Alto Neuroscience fell by nearly 60% during after-hours trading on the same day [2]. Next Steps - Investors who purchased Alto Neuroscience securities and have relevant information are encouraged to assist the investigation by visiting the firm's website [3]. - Contact information for the firm's representatives is provided for those who wish to contribute to the investigation [3]. Legal Representation - The firm represents investors in class actions on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorneys' fees if successful [4]. Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm specializing in securities fraud class actions and has recovered hundreds of millions of dollars for investors [5].
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Alto Neuroscience, Inc. and Encourages Investors to Contact the Firm